Researchers compared billing codes from electronic health records to accurately quantify how many skin cancers patients had.
International Classification of Disease (ICD) codes were a poor proxy measure for the number of skin cancers per patient, according to results of a retrospective cohort study published in JAMA Dermatology. Current Procedural Terminology (CPT) codes were a better proxy measure for the total number of skin cancers per patient, accounting for over 75% of the variability in the number of cancers, the researchers wrote.
Despite keratinocyte cancers being the most common malignant neoplasms among White populations worldwide, they are often not included in cancer registries. In addition, “when data are available, most studies have focused on identifying factors associated with the development of any skin cancer, but many patients develop numerous skin cancers, often with medical records scattered across different health care systems,” the authors explained.
Because having multiple skin cancers is associated with an increased risk for some internal malignant neoplasms and knowledge of the conditions could help providers understand which transplant recipients will respond to prevention treatments, researchers sought to assess the association of the number of CPT and ICD codes with the true number of skin cancers among patients.
Two sets of patients were included in the final analyses, including Vanderbilt University Medical Center’s (VUMC’s) clinical database of patients seen between 2008 and 2018 who had an ICD or CPT code for skin cancer. The second set included patients seen at the center during this time who had at least 1 pathology report showing a skin cancer.
Of the 35,901 patients included, the mean age was around 70 years, while the majority (56.8%) of patients were men and 88.1% where White.
Analyses revealed:
“We observed that the number of CPT codes was strongly correlated with the total number of histologically verified skin cancers, although most patients had a more than 30% discrepancy in the total counts,” the authors wrote.
The researchers were unable to count CPT codes for skin cancers treated topically, with systemic chemotherapy, or with radiation, or those cleared by biopsy. Incidence or prevalence estimates cannot be derived from the findings as the analysis was not a population-based cohort study.
Reference
Anand N, Edwards L, Baker LX, Chren M, Wheless L. Validity of using billing codes from electronic health records to estimate skin cancer counts. JAMA Dermatol. Published online August 11, 2021. doi:10.1001/jamadermatol.2021.2856
Top 5 Most-Read Skin Cancer Articles of 2022
December 23rd 2022BRAF mutations were addressed in depth this year, having been mentioned in 3 of this year’s top 5 articles. Also discussed were a first-in-its-class combination treatment approval and potential indicators of increased skin cancer risk.
Read More
Moderna’s mRNA-4157/V940 combined with Merck’s pembrolizumab reduced melanoma recurrence and death; HHS proposed permanently implementing emergency opioid use disorder policies enacted in 2020; maternal death rates were 62% higher in 2020 in states that now have abortion restrictions.
Read More
Real-world Data Demonstrate Strength, Durability of Checkpoint Inhibitor Use in cSCC
December 10th 2022Response, progression-free survival, overall survival, time-to-next-treatment, and toxicity outcomes were evaluated among patients with advanced cutaneous squamous cell carcinoma (cSCC) who received first-line treatment with immune checkpoint inhibitors.
Read More
Lack of Knowledge Continues to Influence Delayed Melanoma Diagnosis
November 29th 2022Malignant cutaneous melanoma outcomes were investigated as they relate to diagnosis delay and potential influence from socioeconomic and demographic factors in Brazil, where skin cancer diagnoses represent 30% of all cancer diagnoses.
Read More
Risk of Subsequent Skin Cancer Seen Among Organ Transplant Recipients
November 24th 2022The study's goal was to clarify possible second and third skin cancer development patterns among organ transplant recipients who developed more than 1 instance of skin cancer and to better characterize this patient population by patient age and transplanted organ type.
Read More